Evercore ISI Group Maintains Outperform on Akero Therapeutics, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $50 to $60.
September 13, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group maintains an Outperform rating on Akero Therapeutics and raises the price target from $50 to $60.
The news of Evercore ISI Group maintaining an Outperform rating and raising the price target for Akero Therapeutics is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100